• English
  • Korean
  • Chinese
表紙
市場調査レポート - 233891

膀胱癌関連の各種提携動向

Bladder Cancer Partnering 2009-2014

発行 Current Partnering, a division of Wildwood Ventures Limited
出版日 ページ情報 英文
価格
膀胱癌関連の各種提携動向 Bladder Cancer Partnering 2009-2014
出版日: 2014年11月01日 ページ情報: 英文
概要

当レポートでは、膀胱癌治療関連の各種提携契約の動向について調査分析し、大規模提携契約の概要、大手医薬品事業者による各種提携の概要、契約区分・産業部門・開発段階・技術区分別の契約データのディレクトリーなどをまとめ、概略下記の構成でお届けいたします。

エグゼクティブサマリー

第1章 イントロダクション

第2章 膀胱癌関連の各種提携動向

  • イントロダクション
  • 数年におよぶ膀胱癌関連の提携関係
  • 大手製薬事業者の契約活動
  • 各種提携:取引タイプ別
  • 各種提携:産業分野別
  • 各種提携:開発段階別
  • 各種提携:技術タイプ別
  • 公開されている金銭的条件

第3章 主要契約

  • イントロダクション
  • 主要契約:金額別
  • 大手製薬事業者の関わる主要契約

第4章 契約ディレクトリー

  • イントロダクション
  • 企業別(A-Z)
  • 契約タイプ別
    • 資産購入
    • 大手医薬品企業のアウトライセンシング
    • 共同開発
    • 共同R&D
    • 共同マーケティング
    • 業務委託
    • 共同プロモーション
    • CRADA
    • クロスライセンシング
    • 開発
    • 流通販売、など
  • 産業部門別
    • 学術部門
    • 大手製薬
    • バイオテクノロジー
    • ドラッグデリバリー
    • 医療機器
    • 診断
    • ジェネリック薬
    • 政府
    • 非営利
    • 医薬品、など
  • 開発段階別
    • 創薬
    • 前臨床
    • フェーズI
    • フェーズII
    • フェーズIII
    • 申請登録
    • 市販
  • 技術タイプ別
    • 解析
    • 動物モデル
    • アッセイ
    • バイオインフォマティクス
    • 生物学的化合物
    • バイオマテリアル
    • 細胞培養
    • 細胞治療
    • 得印象私権
    • 診断(コンパニオン)
    • 機器、など

第5章 提携のリソースセンター

  • オンラインパートナリング
  • パートナリングイベント
  • 参考資料

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

The Bladder Cancer Partnering 2009-2014 report provides understanding and access to the bladder cancer partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in bladder cancer partnering deals

Top bladder cancer deals by value

Deals listed by company A-Z, industry sector, stage of development, technology type

Description

The Bladder Cancer Partnering 2009-2014 provides understanding and access to the bladder cancer partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of bladder cancer partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors bladder cancer technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This data driven report contains over 25 links to online copies of actual bladder cancer deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of bladder cancer partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in bladder cancer partnering since 2009, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.

Chapter 3 provides an overview of the leading bladder cancer deals since 2009. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive directory of bladder cancer partnering deals signed and announced since 2009. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the

research, development and commercialization of bladder cancer technologies and products.

Report scope

Bladder Cancer Partnering 2009-2014 is intended to provide the reader with an in-depth understanding and access to bladder cancer trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

  • Trends in bladder cancer dealmaking in the biopharma industry since 2009
  • Access to summary headline, upfront, milestone and royalty data
  • Access to over 25 bladder cancer contract documents
  • The leading bladder cancer deals by value since 2009

In Bladder Cancer Partnering 2009-2014, the available deals are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Company A-Z
  • Industry sector
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Benefits

Bladder Cancer Partnering 2009-2014 provides the reader with the following key benefits:

  • In-depth understanding of bladder cancer deal trends since 2009
  • Access to summary headline, upfront, milestone and royalty data
  • Comprehensive access to over 25 actual bladder cancer deals entered into by the world's biopharma companies since 2009
  • Insight into key deal terms included in contracts, where disclosed
  • Understand the key deal terms companies have agreed in deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in bladder cancer partnering

  • 2.1. Introduction
  • 2.2. Bladder cancer partnering over the years
  • 2.3. Bigpharma bladder cancer dealmaking activity
  • 2.4. Bladder cancer partnering by deal type
  • 2.5. Bladder cancer partnering industry sector
  • 2.6. Bladder cancer partnering by stage of development
  • 2.7. Bladder cancer partnering by technology type
  • 2.8. Disclosed financial deal terms for bladder cancer partnering
    • 2.8.1 Bladder cancer headline values
    • 2.8.2 Bladder cancer upfront payments
    • 2.8.3 Bladder cancer milestone payments
    • 2.8.4 Bladder cancer royalty rates

Chapter 3 - Leading bladder cancer deals

  • 3.1. Introduction
  • 3.2. Top bladder cancer deals by value
  • 3.3. Top bladder cancer deals involving bigpharma

Chapter 4 - Dealmaking directory

  • 4.1. Introduction
  • 4.2. Company A-Z
  • 4.3. By deal type
  • Asset purchase
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Contract service
  • Co-promotion
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Manufacturing
  • Marketing
  • Option
  • Promotion
  • Research
  • Settlement
  • Spin out
  • Sub-license
  • Supply
  • Termination
  • 4.4. By industry sector
  • Academic
  • Bigpharma
  • Biotech
  • Drug delivery
  • Medical device
  • Diagnostic
  • Generic pharma
  • Government
  • Non-profit
  • Pharmaceutical
  • Research tools
  • Services
  • Specialty pharma
  • 4.5. By stage of development
  • Discovery
  • Pre-clinical
  • Phase I
  • Phase II
  • Phase III
  • Registration
  • Marketed
  • 4.6. By technology type
  • Analysis
  • Animal models
  • Assays
  • Bioinformatics
  • Biological compounds
  • Biomarkers
  • Biomaterials
  • Cell culture
  • Cell therapy
  • Clinical testing
  • Diagnostic - companion
  • Devices
  • Diagnostics
  • Discovery tools
  • DNA probes
  • Drug delivery
  • Enabling technology
  • Epigenetics
  • Equipment
  • Facilities
  • Gene therapy
  • Genomics
  • Imaging
  • Industrial chemicals
  • In vitro models
  • Monoclonal antibodies
  • Nanotechnology
  • Oligonucleotide
  • Peptides
  • Personalised medicine
  • Processes
  • Proteomics
  • Radio/Chemo-therapy
  • Recombinant DNA
  • Research services
  • Research supplies
  • RNA therapeutics
  • Screening
  • Small molecules
  • Stem cells
  • Vaccines

Chapter 5 - Partnering resource center

  • 5.1. Online partnering
  • 5.2. Partnering events
  • 5.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent titles from CurrentPartnering
  • Order Form - Reports
  • Table of figures
  • Figure 1: Bladder cancer partnering since 2009
  • Figure 2: Bigpharma - top 50 - bladder cancer deals 2009 to 2011
  • Figure 3: Bigpharma bladder cancer deal frequency - 2009 to 2011
  • Figure 4: Bladder cancer partnering by deal type since 2009
  • Figure 5: Bladder cancer partnering by industry sector since 2009
  • Figure 6: Bladder cancer partnering by stage of development since 2009
  • Figure 7: Bladder cancer partnering by technology type since 2009
  • Figure 8: Bladder cancer deals with a headline value
  • Figure 9: Bladder cancer deals with upfront payment values
  • Figure 10: Bladder cancer deals with milestone payments
  • Figure 11: Bladder cancer deals with royalty rates, %
  • Figure 12: Top bladder cancer deals by value since 2009
  • Figure 13: Top bladder cancer deals signed by bigpharma value since 2009
  • Figure 14: Online partnering resources
  • Figure 15: Forthcoming partnering events
  • Figure 16: Deal type definitions
Back to Top